Journal: Scientific reports

Article Title: PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

doi: 10.1038/s41598-022-16623-3

Figure Lengend Snippet: Figure 2. Cell line-dependent reversibility of acquired Talazoparib resistance. (a) Immunoblot showing PAR level of PSN1 parental cells, TalaR cells maintained in media with Talazoparib (TalaR-M) and TalaR cells cultured in drug-free media for 4 weeks (TalaR-DF). (b) Talazoparib IC50 chart showing reversibility of acquired resistance in PSN1 cells over 4 weeks after drug withdrawal. (c–f) Clonogenic assay showing Talazoparib sensitivity of parental and acquired resistant cells in PSN1, PANC1, SW1990 and HCC1806 cells which were maintained in drug media (Tala-M) and in drug free media for 4 weeks (Tala-DF). (g, h) Volcano plots showing differentially expressed genes between TalaR-M and TalaR-DF in PSN1 and HCC1806 cells. (i, j) UMAP representations of HCC1806 parental and resistant subpools, colored by cell line (i) or cluster identity (j). (k, l) Violin plots of SNAI2 (k) and TWIST1 (l) gene expression profile across subpopulation clusters shown in (j).

Article Snippet: SNAI2 cDNA expressing plasmid was purchased from Origene (RC202365) and transfected into cells by using Fugene HD transfection reagent (Promega).

Techniques: Western Blot, Cell Culture, Clonogenic Assay, Gene Expression

Journal: Scientific reports

Article Title: PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.

doi: 10.1038/s41598-022-16623-3

Figure Lengend Snippet: Figure 5. CHD1L depletion re-sensitizes cells with acquired resistance to Talazoparib. (a) Clonogenic assay showing growth of PSN1 TalaR-M cells with CHD1L stable knockdown. (b) Immunoblot showing expression level of CHD1L and SNAI2 in CHD1L stable knockdown cells as in (a). (c) IncuCyte curves showing the growth PSN1 TalaR-M with inducible CHD1L knockdown with and without doxycycline induction. (d) qPCR showing mRNA level of CHD1L and SNAI2 in PSN1 TalaR-M with inducible CHD1L knockdown with and without doxycycline induction as in (c). (e) IncuCyte curves showing the growth of PSN1 parental and TalaR-M with CHD1L knockout. (f) IncuCyte curves showing the growth of HCC1806 parental and TalaR-M with CHD1L knockout. (g, h) Immunoblot and qPCR showing CHD1L and SNAI2 level in HCC1806 parental and TalaR-M with CHD1L knockout as in (f).

Article Snippet: SNAI2 cDNA expressing plasmid was purchased from Origene (RC202365) and transfected into cells by using Fugene HD transfection reagent (Promega).

Techniques: Clonogenic Assay, Knockdown, Western Blot, Expressing, Knock-Out

Journal: iScience

Article Title: N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

doi: 10.1016/j.isci.2024.108956

Figure Lengend Snippet:

Article Snippet: The primary antibodies used were anti-B7-H3 (1:400; Proteintech, Cat No. 14453-1-AP), anti-ALDH (1:100; Abcepta, Cat No. AP1465c), anti-CD133 (1:500; Abcam, Cat No. ab27699), anti-MYC (1:500; Abcam, Cat No. ab18185), anti-NANOG (1:500; Novus, Cat No. NB100-58842), anti-SOX2 (1:300; Novus, Cat No. NB110-79875), anti-Ki67 (1:200; Proteintech, Cat No. 27309-1-AP), anti-Slug (1:1000; OriGene, Cat No. TA800167), anti-N-cadherin (1:5000; Proteintech, Cat No. 22018-1-AP) and anti-E-cadherin (1:2000; OriGene, Cat No. TA800692).

Techniques: Recombinant, Software